IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis

M. Vis; W.H. Bos; G. Wolbink; A.E. Voskuijl; J.W.R. Twisk; R van de Stadt; D. Hamann; B.A.C. Dijkmans; W.F. Lems

IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis

M. Vis
, W.H. Bos
, G. Wolbink
, A.E. Voskuijl
, J.W.R. Twisk
, R van de Stadt
, D. Hamann
, B.A.C. Dijkmans
, W.F. Lems

Methodology and Applied Biostatistics

Research output: Contribution to Journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	425-428
Journal	Journal of Rheumatology
Volume	35
Issue number	3
Publication status	Published - 2008

Persistent URL (handle)

Persistent link

Cite this

Vis, M., Bos, W. H., Wolbink, G., Voskuijl, A. E., Twisk, J. W. R., van de Stadt, R., Hamann, D., Dijkmans, B. A. C., & Lems, W. F. (2008). IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. Journal of Rheumatology, 35(3), 425-428.

@article{66d96c52015d4a77bea847e21d9052b4,

title = "IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis",

author = "M. Vis and W.H. Bos and G. Wolbink and A.E. Voskuijl and J.W.R. Twisk and \{van de Stadt\}, R and D. Hamann and B.A.C. Dijkmans and W.F. Lems",

year = "2008",

language = "English",

volume = "35",

pages = "425--428",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "3",

}

Vis, M, Bos, WH, Wolbink, G, Voskuijl, AE, Twisk, JWR, van de Stadt, R, Hamann, D, Dijkmans, BAC & Lems, WF 2008, 'IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis', Journal of Rheumatology, vol. 35, no. 3, pp. 425-428.

IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. / Vis, M.; Bos, W.H.; Wolbink, G. et al.
In: Journal of Rheumatology, Vol. 35, No. 3, 2008, p. 425-428.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis

AU - Vis, M.

AU - Bos, W.H.

AU - Wolbink, G.

AU - Voskuijl, A.E.

AU - Twisk, J.W.R.

AU - van de Stadt, R

AU - Hamann, D.

AU - Dijkmans, B.A.C.

AU - Lems, W.F.

PY - 2008

Y1 - 2008

M3 - Article

SN - 0315-162X

VL - 35

SP - 425

EP - 428

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 3

ER -